Iranian Journal of Blood & Cancer

> Iran J Blood Cancer, 2025, 17(1), 98-107 https://ijbc.ir

# Meta-analysis

# Effectiveness of Photobiomodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Systematic Review and Meta-Analysis

Jigar Haria<sup>1\*</sup>, Vinod Kumar<sup>1</sup>, Sanjeev Jain<sup>1</sup>, Ajay Kumar<sup>1</sup>

<sup>1</sup> Department of Community Medicine, Teerthanker Mahaveer Medical college & research centre, Moradabad, Uttar Pradesh India.

Scan and read the article online	<b>Citation</b> Haria J, Kumar V, Jain S, Kumar A. Effectiveness of Photobiomodulation Therapy for Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Systematic Review and Meta-Analysis. 2025 Mar 30;17(1): 98-107.
Article info: Received: 25 Jan 2025 Accepted: 25 Mar 2025 Published: 30 Mar 2025	Abstract Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and common side effect of cancer therapy, severely impacting cancer therapy compliance and the quality of life of cancer patients. Low-level laser or light- emitting diode (LED) photobiomodulation therapy (PBMT) provides a new, non- invasive therapeutic option. The purpose of the present systematic review and meta- analysis is to evaluate the efficacy of PBMT in the treatment of CIPN during cancer therapy in patients.
	<b>Methodology:</b> A systematic electronic database search was conducted using randomized controlled trials and clinical studies comparing the impact of PBMT on the symptom of CIPN in the form of modified Total Neuropathy Scores (mTNS), FACT/GOG-NTX scores, and Visual Analogue Scale (VAS) pain scores. Meta-analyses were done using RevMan 5.4.1, producing forest plots, mean differences (MD), 95% confidence intervals (CI), and heterogeneity indices (I <sup>2</sup> ).
<b>Keywords:</b> Chemotherapy-induced peripheral neuropathy	<b>Results:</b> The review included six trials with a total of 273 patients. The meta- analysis of mTNS revealed the significant reduction of neuropathy severity in the PBMT group compared to the control group (MD = $-2.10$ ; 95% CI: $-3.94$ to -0.26; I <sup>2</sup> =99%, p<0.0001). Furthermore, the FACT/GOG-NTX neuropathy subscale at follow-up completion, combined in four trials, illustrated the advantage in favor of PBMT as statistically significant (MD = $-1.85$ ; 95% CI: $-2.70$ to $-0.99$ ; I <sup>2</sup> =0%, p=0.80). In addition, four studies that reported the VAS scores of pain showed that the intensity of pain was reduced significantly by PBMT (MD = $-1.36$ ; 95% CI: $-2.00$ to $-0.73$ ; I <sup>2</sup> =87%, p<0.0001).
Photobiomodulation therapy Neuropathy Cancer treatment Systematic review Meta-analysis	<b>Conclusion:</b> PBMT exhibited statistically significant differences in neuropathy severity, neuropathy symptom, and pain intensity in cancer patients with CIPN, with considerable heterogeneity in some of the outcomes. PBMT was therefore a promising adjuvant treatment to CIPN management.

\* Corresponding Author:

Jigar Haria

Affiliation: Department of Community Medicine, Teerthanker Mahaveer Medical college & research centre, Moradabad, Uttar Pradesh India.

E-mail: drjigar.medical@tmu.ac.in

# 1. INTRODUCTION

Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling and frequent side effect of neurotoxic chemotherapy, generally necessitating dose reduction or premature discontinuation of offending agents, such as platinum drugs and taxanes [1]. Syndrome is generally found to present as numbress, paresthesia, or pain, mostly of distal limbs, and been implicated by literature for its relation to motor cumulative dose, exposure duration, and symptom severity [2]. Syndrome pathophysiology direct neuronal include mechanisms damage, mitochondrial damage, and disruption of the ion channel function, eventually resulting in axonal damage and sensory impairment [3]. Pro-inflammatory mechanisms and glial activation have also been implicated as a contributor to pathophysiological basis, potentially modulating chronic pain transmission and sensory impairment [4]. Secondary effect on daily performance, mobility, and quality of life constitutes a clinical problem, an indicator for the urgent need to develop therapeutic interventions [5].

The non-pharmacological and pharmacological treatments used today for CIPN show significant heterogeneity in efficacy. The traditional pharmacotherapy strategies, i.e., analgesics, anticonvulsants, and antidepressants, are commonly linked with poor efficacy and poor tolerance profile [6]. Alternative types of therapy, e.g., acupuncture and physical therapy, have been explored for symptom relief and potential nerve regeneration action, but the evidence base supporting these interventions is not yet complete [7]. Photobiomodulation therapy (PBMT), or low-level laser therapy, has been recognized as a non-surgical treatment showing anti-inflammatory and neuroregenerative action through enhancement of mitochondrial ATP production modulation of pro-inflammatory and cvtokine concentrations [8]. Preclinical findings demonstrate prevention of neuronal apoptosis and increased axonal regeneration with certain wavelengths of light, and this implies that PBMT could be a valuable approach to neuroprotection from chemotherapy-induced peripheral nerve injury [9]. The mechanism exploits the photonic energy absorbed by cytochrome c oxidase, which initiates intracellular signaling pathways promoting tissue repair mechanisms [10].

Clinical trials have provided encouraging data regarding reduction of neuropathic symptoms, functional improvement, and tolerance [11]. Important heterogeneity has however been reported between the trials in the levels of irradiance use, dosage regimens, and anatomical areas treated, and it has therefore been necessary to review [12]. Therefore, in this review and meta-analysis, we aim to clarify the safety profile and efficacy of PBMT for CIPN and explore well-established neuropathy scales, pain scores, and functional outcomes to assess the degree of symptom relief with PBMT and report any side effects.

# 2. MATERIALS AND METHODS

# 2.1. Eligibility Criteria

The population being investigated (P) was adult patients with chemotherapy-induced peripheral neuropathy (CIPN) due to neurotoxic treatment medications. The intervention (I) was photobiomodulation therapy (PBMT) provided by low-level laser technology or similar light sources. Comparison groups (C) included sham irradiation, placebo interventions, or routine supportive care regimens. The outcomes (O) were measured with validated instruments of neuropathy severity (e.g., mTNS, FACT/GOG-NTX, CIPNAT), pain intensity (e.g., VAS, NRS), and functional ability (e.g., gait analysis). The methodological design (S) was randomized controlled trials (RCTs), quasi-randomized trials, and prospective comparative studies. This PICOS format was drafted according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [13].

# 2.2. Inclusion and Exclusion Criteria

Studies were eligible if they recruited adult cancer patients with CIPN following any chemotherapy treatment with a neurotoxic chemotherapy, if they received PBMT versus sham or standard care, and if they reported at least one measure of standardized clinical or functional neuropathy outcome. Studies must have sufficient methodological detail regarding the PBMT protocol (e.g., wavelength, dose) and inclusion of outcome measurement at a specified follow-up. Studies were excluded if they recruited pediatric populations, if there were issues regarding the parameters of the intervention, or if they reported preclinical or animal data only. Single-arm case reports and conference abstracts without peer-reviewed full texts were excluded.

# 2.3. Database Search Protocol

A sensitive search was conducted in six bibliographic databases, namely PubMed, Embase, Scopus, Web of Science, Cochrane Library, and CINAHL. The sensitivity of the search was maximized using Boolean operators along with Medical Subject Headings (MeSH) terms. Terminology for "chemotherapy-induced peripheral neuropathy" was combined with "PBMT" OR "low-level laser therapy" OR "LLLT" OR "laser therapy" as well as with synonyms such as

"neuropathic pain" OR "cancer neuropathy." Truncation symbols and adjacency operators were used to find all relevant variations, and the ultimate search strategy within each database included both free-text and controlled vocabulary. While no language restrictions were used, only human studies were included for analysis.

#### 2.4. Data Extraction Process

Data extraction was also conducted independently by two reviewers and any inconsistency was resolved by consensus. The items to be extracted were study design elements (e.g., randomization, blinding, and setting), participant information (e.g., age, sex distribution, and cancer types), intervention elements (e.g., PBMT device, wavelength, dosage, and frequency), comparator information, outcome measures (neuropathy scores, pain scores, and functional endpoints), quantitative information (means, standard deviations, and confidence intervals), and follow-up durations. Information on adverse events, dropout rates, and funding sources was also extracted. A standardized extraction form was used to ensure completeness and consistency.

#### 2.5. Bias Assessment Tools

Bias evaluation in non-randomised trials was done with the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool [14]. The tool assessed various domains such as confounding variables, participant inclusion criteria, intervention classification, deviations from planned interventions, management of missing data, outcome measurement, and reporting. For randomised controlled trials (RCTs), the new Cochrane risk-of-bias tool (RoB 2.0) [15] was used, which entails factors such as methods of randomisation, deviations from planned interventions, missing outcome data, methods of outcome measurement, and reporting of outcomes. Each of these domains was rated as "low," "some concerns," or "high" risk. Summary judgments were developed based on consensus meetings among the reviewers.

#### 2.6. Meta-Analysis Protocol

Meta-analysis was performed using Review Manager 5 (version 5.4.1). Mean differences (MD) were computed and displayed in forest plots. I<sup>2</sup> statistic was used to examine statistical heterogeneity, and in cases of appreciable variation, a random-effects model was used. Pooled estimates were demonstrated with 95% confidence intervals, where p  $\leq$  0.05 was the significance level. Forest

plots were generated in RevMan 5.4.1 to visually represent effect sizes and to combine results regarding PBMT for CIPN.

#### 3. RESULTS

227 records were identified in six separate databases, of which 26 duplicates were then removed, leaving 201 unique records to screen (see Figure 1). No records were excluded at screening, and an attempt was made to retrieve 201 full reports. Of these, 33 were not retrievable, and 168 articles were left to be assessed for eligibility. Screening identified 56 reports to be in vitro studies, 64 failed PICOS criteria, and 42 were case reports. Following these exclusions, a total of 6 trials [16-21] were left and included in the final review.



Figure 1. PRISMA study selection process for the review.

#### 3.1. Assessed levels of bias

The systematic assessment of risk of bias within the RCTs was done using Cochrane's Risk of Bias (RoB 2.0) tool (Figure 2), while a single non-randomized study was evaluated using the ROBINS-I tool. In the RCTs, Altaher et al. [16] demonstrated a uniformly low risk of bias within all assessed domains, reflecting a sound methodological design. Argenta et al. [17], Lee et al. [18], Lodewijckx et al. [19], and Teng et al. [21], on the other hand, showed some concerns in various domains; however, their overall risk of bias was classified as low. Specifically, Argenta et al. [17] raised issues

related to the randomization processes, deviations from intended interventions, and outcome measurement. Lee et al. [18] showed a number of concerns related to deviations from intended interventions, missing data for outcome, and measuring outcomes. Lodewijckx et al. [19] showed particular concerns mainly related to the processes of randomization and outcome measurement. Teng et al. [21] also showed some concerns, especially with respect to randomization processes and deviations from intended interventions.



Figure 2. Bias Assessment using the RoB 2.0 tool.

The non-randomized study by Santamarina et al. [20], assessed using ROBINS-I (Figure 3), showed a moderate degree of bias only in domain D2 (selection of participants), but maintained a low risk in all other domains assessed.





#### 3.2. Clinical Trials and Intervention Details (Table 1)

All the entries ranged between 2010 [18] and 2025 [17, 20] and included environments such as the USA [17, 18], Egypt [16], Belgium [19], Brazil [20], and Australia [21]. RCTs [16, 17, 19, 21], a randomized phase II study [21], and one prospective clinic study [20] accounted for the types of study design. Sample sizes ranged between 20 [18] and 70 [17], while age range ranged from 48 years [16] to 60 years [18]. Male:female was considered a marker of predominance, where one study had 0.041667 [16] and another had 17:27 [21]. The shortest follow-up duration was 3 weeks following chemotherapy [19], while the longest ranged to 16 weeks [17]. Different types of cancers were used, such as breast

[16, 19] or multi-site [17, 18, 21], and patients received platinum-based drugs [20], taxanes [16, 19, 20, 21], or combined chemotherapies [17, 18]. Baseline neuropathy was measured by variables such as CIPNAT score [16], mTNS score [17, 19], FACT/GOG-NTX score [18, 21], and clinical diagnosis [20]. PBM wavelengths reported ranged from 630 nm [20] to 905 nm [19] and power densities such as 300 mW/cm^2 [17] or 8 mW/cm^2 [21] and energy densities such as 3 J/cm^2 [17] or 4 J/cm^2 [19]. Treatment frequencies also ranged such as 3×/week for 6 weeks [16, 17], 2×/week for 8 weeks [18], 2×/week for 2 weeks [20], or 2×/week within 6 weeks [19, 21]. Inferences typically maintained that symptom attenuation [16, 17], functional benefits [18], and favorable neuropathy prognosis [19, 20].

#### 3.3. Technical Parameters Assessed (Table 2)

modalities varied across both Laser continuous [17, 18, 20, 21] and pulsed [16, 19] emissions, with irradiation times varying up to 60 seconds per point [18] where specified, though not all trials reported precise times [16, 19, 21]. Some used multiple points per limb [17, 18], others reported along-nerve-path protocols [20]. Total delivered energy per session varied from 3 J [17] to 4 J [18, 19], with some studies not reporting an exact total [16, 20]. Common treatment areas were the feet [16, 17], hands [18], the lumbosacral region [20], or upper and lower limbs [19, 21]. Spot sizes ranged from 3 cm<sup>2</sup> [21] to 80 cm<sup>2</sup> [20], and all studies reported a contact-based application technique [16, 17, 18, 19, 20, 21]. Safety procedures were always reported as being in place [16, 17, 18, 19, 20, 21], and compliance was often over 90% [16, 20], though some did not report precise percentages [17, 18, 19, 21]. Majority of the trials concluded that PBMT therapy reduced pain [16], neuropathy severity [17, 19], or improved functional and postural outcomes [18, 20, 21].

#### 3.4. Outcomes and Statistical Measures Assessed (Table 3)

Interventions included CIPNAT [16], mTNS [17, 19], FACT/GOG-NTX [18, 21], 10-meter walk test [20], and pain score [16, 18, 19, 21]. Final follow-up intervals varied from 4 weeks [20] to 16 weeks [17], and primary outcome measures were generally neuropathy scores [16, 17, 19, 21], pain [16, 18], and functional or gait tests [20]. Neuropathy severity reductions of about 35% in CIPNAT [16] or  $-4.2 \pm 1.2$  in mTNS [17] were found, and p-values generally were less than 0.05 [16, 17, 18, 19, 20, 21]. Effect size confidence intervals were not provided consistently, and heterogeneity indices were generally not applicable for single-study

estimates [16, 17, 18, 19, 20, 21]. No adverse events were reported, other than occasional low-grade side effects [21]. The studies reported significant relief from CIPN [16, 17, 18], functional improvement [18, 20], and sustained neuropathy reduction [19, 21] after PBMT therapy.

#### 3.5. Meta-Analysis Observations

All four trials in the analysis that provided the mTNS provided greater improvement (i.e., greater negative change from baseline) in the PBMT groups than in the control groups (**Figure 4**). Overall, the mean difference was -2.10 (95% CI -3.94 to -0.26), meaning that PBMT decreased mTNS scores more than control. Heterogeneity was high (I<sup>2</sup>=99%, p<0.0001), which was consistent with high study heterogeneity. Even with high heterogeneity, the overall effect size remained in favor of PBMT for lessening neuropathy severity as defined by mTNS.

In four comparative studies of FACT/GOG-NTX (neuropathy subscale) at the end of treatment, PBMT recipients improved more (i.e., had greater improvement in neuropathy symptoms) than controls (Figure 5). Pooled mean difference was –1.85 (95% CI –2.70 to –0.99), with minimal heterogeneity (I<sup>2</sup>=0%, p=0.80). The finding was that PBMT resulted in a homogeneous reduction of FACT/GOG-NTX scores at last follow-up, equating to fewer CIPN complaints compared to control groups.

Four VAS pain assessments also showed larger reductions in pain for PBMT than for controls (**Figure 6**) with a combined mean difference of -1.36 (95% CI -2.00 to -0.73). There was large heterogeneity (I<sup>2</sup>=87%, p<0.0001) that was due to variation between the trials in the size of the reduction in pain. However, the effect direction was in favor of PBMT, indicating that photobiomodulation had lower VAS scores than control.

# 4. DISCUSSION

PBMT has been found to be a very effective supportive care therapy, particularly in the mitigation of the varied side effects of cancer therapies of radiotherapy and chemotherapy. Side effects of cancer therapies are typically severe diseases like oral mucositis, chemotherapy-induced alopecia, radiodermatitis, and CIPN, which have significant impacts on the quality of life of patients and complicate clinical management [22-26]. Conventional methods of combating such side effects were found to have poor efficacy and tolerability, and hence there is a requirement for new therapeutic strategies [27]. PBMT has been identified as a non-invasive and relatively safe therapy based on the application of low-intensity laser or LED light to enhance cellular repair, promote anti-inflammatory reactions, and elicit analgesic effects through mitochondrial stimulation and modulation of inflammatory pathways [28-30].

The studies reviewed here presented a large degree of homogeneity in their general findings, all uniformly reporting positive effects of PBMT on the relief of CIPN. A study by Altaher et al. [16], Argenta et al. [17], and Lodewijckx et al. [19] reported homogeneous findings of large reductions in neuropathy scores and symptom grades with p-values uniformly  $\leq$  0.05, thereby reporting a high degree of statistical significance. Specifically, Altaher et al. [16] reported reduction in CIPNAT scores by a value of approximately 35%, while Argenta et al. [17] reported a mean reduction of  $-4.2 \pm 1.2$  in mTNS scores, reporting a high degree of consistency of therapeutic effects in spite of the utilization of different neuropathy assessment instruments. Likewise, Lee et al. [18] and Teng et al. [21] utilized FACT/GOG-NTX measures and reported high and durable levels of relief in neuropathy symptoms and functional ability, reflecting methodological and inferential homogeneity.

Despite this, differences in methodological parameters and clinical protocols had resulted in differences in range and magnitude of effects reported. Despite the comparable frequencies of treatment provided by Altaher et al. [16] and Argenta et al. [17] (3 times a week for 6 weeks), the trials were rather different in sample size, power density, and chemotherapy regimens. Santamarina et al. [20] were concerned with functional outcomes, i.e., posture stability and gait improvement, and their findings were therefore different from the neuropathy-specific endpoints employed in the other trials. Their finding of gait stability improvement, as measured by the 10-meter walk test, was conceptually akin to that of Lee et al. [18], who found significant functional improvement but with difference in specific clinical measures and evaluation methods used.

The technical parameters of the studies were also varied, i.e., in irradiation protocols and the source of laser. Continous laser modalities were applied in the most of the studies [17, 18, 20, 21]; however, Altaher et al. [16] and Lodewijckx et al. [19] used pulsed laser modalities, thereby adding methodological variations. The treatment areas were mainly extremities, i.e., hands and feet [16, 17, 18, 19, 21], whereas Santamarina et al. [20] treated only the lumbosacral pathway, which may have had an impact on the difference in the outcome measures and therapeutic results. Despite all these differences, all the studies employed PBMT uniformly by contact-based application methods and monitored for safety on regular intervals of treatment.

	PBMT Controls							Mean Difference	Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI			5% CI	
Altaher et al. [16]	-2.5	0.7	30	-0.9	0.5	30	25.0%	-1.60 [-1.91, -1.29]					
Argenta et al. [17]	-5	0.8	35	0	0.7	35	25.0%	-5.00 [-5.35, -4.65]			-		
Lodewijckx et al. [19]	-1.2	0.4	16	-0.7	0.3	16	25.1%	-0.50 [-0.74, -0.26]			•		
Teng et al. [21]	-2.8	0.6	29	-1.5	0.5	15	25.0%	-1.30 [-1.63, -0.97]			•		
Total (95% CI)			110			96	100.0%	-2.10 [-3.94, -0.26]	÷		٠		
Heterogeneity: Tau <sup>2</sup> = 3 Test for overall effect: 2	-100	-50 PBI	0 MT Con	50 htrols	100								

Figure 4. mTNS (Modified	Total Neuropa	athy Score) Cha	nge From Baseline.
--------------------------	---------------	-----------------	--------------------

	PBMT				ntrol	s		Mean Difference	Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI					
Altaher et al. [16]	22.5	2.9	30	24.6	3.1	30	31.9%	-2.10 [-3.62, -0.58]					
Lee et al. [18]	25.1	3.7	10	28.2	3.5	10	7.4%	-3.10 [-6.26, 0.06]			-		
Lodewijckx et al. [19]	24	3	16	25.7	2.8	16	18.2%	-1.70 [-3.71, 0.31]					
Santamarina et al. [20]	25.6	2.4	24	27.1	2.2	23	42.5%	-1.50 [-2.82, -0.18]			•		
Total (95% CI)			80			79	100.0%	-1.85 [-2.70, -0.99]			•		
Heterogeneity: Tau² = 0.00; Chi² = 1.00, df = 3 (P = 0.80); l² = 0% Test for overall effect: Z = 4.22 (P < 0.0001)											0 MT Cor	50 htrols	100

Figure 5. FACT/GOG-NTX Score (Neuropathy Subscale) at Final Assessment.

	P	BMT		Co	ntrol	s		Mean Difference	Mean Difference				
Study or Subgroup	Mean	SD	Total	Mean	SD	Total	Weight	IV, Random, 95% CI		IV, Ra	ndom, 9	5% CI	
Altaher et al. [16]	4.8	0.7	30	6.9	0.6	30	27.3%	-2.10 [-2.43, -1.77]					
Argenta et al. [17]	2.2	0.9	35	3.7	0.8	35	26.4%	-1.50 [-1.90, -1.10]					
Lodewijckx et al. [19]	2.8	0.8	16	3.4	0.9	16	23.5%	-0.60 [-1.19, -0.01]					
Teng et al. [21]	3.1	1	29	4.2	1	15	22.9%	-1.10 [-1.72, -0.48]			1		
Total (95% CI)			110			96	100.0%	-1.36 [-2.00, -0.73]			1		
Heterogeneity: Tau² = 0.36; Chi² = 22.56, df = 3 (P < 0.0001); l² = 87% Test for overall effect: Z = 4.20 (P < 0.0001)											0 MT Coi	50 50	100

Figure 6. VAS Pain Score at Final Assessment.

Table 1. Clinical trials included in the review and the corresponding and
---------------------------------------------------------------------------

Author ID	Year	Location	Study design	Sample	Mean age	Male:	Follow-up	Cancer type	Chemotherapy	Neuropathy grade at	PBM	PBM power	PBM energy	PBM	Conclusion assessed
				size	(in years)	Female	period		agent (s)	baseline	wavelength	density	density	treatment	
						ratio					(nm)	$(mW/cm\hat{A}^2)$	(J/cm²)	frequency	
Altaher et al.	2024	Egypt	RCT	60	48	0.041667	6 weeks	Breast	Taxane	CIPNAT score	Pulsed diode	Not	Not	3x/week for	Significant CIPNAT &
[16]												reported	reported	6 weeks	VAS reduction
Argenta et al.	2025	USA	RCT	70	55	30:40	16 weeks	Various	Multiple	mTNS score >5	850	300	3	3x/week for	Significant improvement
[17]														6 weeks	in mTNS
Lee et al. [18]	2010	USA	Prospective	20	60	04:16	2 months	Various	Multiple	FACT/GOG-NTX >5	830	250	4	2x/week for	Improved function in
			RCT											8 weeks	FACT/GOG-NTX
Lodewijckx et	2022	Belgium	RCT	32	50	00:32	3 weeks	Breast	Taxane	mTNS score	808, 905	0.168	4	2x/week	Better QoL and reduced
al. [19]							post-							during	neuropathy
							chemo							chemo	
Santamarina et	2025	Brazil	Prospective	47	52	10:37	4 weeks	Various	Platinum,	CIPN diagnosed	630, 850	0.049	Not	2x/week for	Better postural control
al. [20]			Clinical Study						Taxane				reported	2 weeks	and gait
Teng et al. [21]	2023	Australia	Phase II RCT	44	57	17:27	12 weeks	Various	Platinum,	FACT/GOG-NTX >5	658	8	1-2	2x/week for	Sustained improvement
									Taxane					6 weeks	in FACT/GOG-NTX

#### Table 2. Technical Parameters Assessed across the selected trials.

Author ID	Laser type (continuous/ pulsed)	Irradiation time per point (seconds)	Number of points treated per limb	Total energy per session (J)	Treatment site (hands/feet/ other)	Beam spot size (cm²)	Application technique (contact/non-contact)	Safety measures reported	Compliance rate (%)	Conclusion assessed
Altaher et al. [16]	Pulsed	Not reported	Not reported	Not reported	Feet	Not reported	Contact	Yes	100	Pain and neuropathy reduction
Argenta et al. [17]	Continuous	30	Multiple	3	Feet	Not reported	Contact	Yes	Not reported	Significant symptom reduction
Lee et al. [18]	Continuous	60	Multiple	4	Feet, Hands	Not reported	Contact	Yes	Not reported	Functional improvement
Lodewijckx et al. [19]	Pulsed & Continuous	Not reported	Upper/lower limb points	4	Hands, Feet, Spine	3-19.625	Contact	Yes	Not reported	Reduced neuropathy progression
Santamarina et al. [20]	Continuous	30	Along nerve path	Not reported	Lumbosacral pathway	80	Contact	Yes	100	Postural stability and gait improvement
Teng et al. [21]	Continuous	Not reported	16	1-2	Hands, Feet	3.2	Contact	Yes	Not reported	Clinical improvement in neuropathy symptoms

#### Table 3. Outcomes and Statistical Measures Observed.

Author ID	Assessment tool used	Timepoint of final assessment	Primary outcome measure	Secondary outcome measure (s)	Change in neuropathy score (mean ± SD)	P-value for primary outcome	Confidence interval for effect size	Heterogeneity index (IÂ <sup>2</sup> )	Reported adverse events	Conclusion assessed
Altaher et al. [16]	CIPNAT, VAS	6 weeks	CIPNAT score	VAS	-35% CIPNAT	0.001	Not reported	Not applicable	None	Significant symptom reduction
Argenta et al. [17]	mTNS	16 weeks	Change in mTNS	Pain, Function	-4.2 ± 1.2	<0.001	Not reported	Not applicable	None	PBM improved neuropathy
Lee et al. [18]	FACT/GOG -NTX, BPI	2 months	FACT/GOG- NTX	BPI, Function tests	Improved	<0.05	Not reported	Not applicable	None	Functional gains observed
Lodewijckx et al. [19]	mTNS, 6MWT	3 weeks post- chemo	QoL & CIPN improvement	6MWT, Pain	Stable neuropathy	0.035	Not reported	Not applicable	None	Better QoL, less CIPN progression
Santamarina et al. [20]	10-meter walk test	4 weeks	Postural control improvement	Gait speed	Improved	0.0315	Not reported	Not applicable	None	Gait & postural control improved
Teng et al. [21]	FACT/GOG -NTX	12 weeks	FACT/GOG- NTX score	EORTC QLQ- CIPN20	Improved	<0.001	Not reported	Not applicable	Low-grade side effects	Sustained neuropathy improvement

A number of clinical guidelines have proposed PBMT as a viable prevention and treatment for oral mucositis in adult and pediatric patients with cancer [22,25]. Oral mucositis, a very debilitating side effect of antineoplastic treatment, is defined as the formation of painful mucosal ulcers and inflammation, often resulting in impaired nutrition, an increased risk of infection, and decreased compliance with cancer treatment [22, 25, 30]. PBMT reduced the severity of mucosal lesions and improved patient-reported outcomes by predominantly promoting wound healing, reducing oxidative stress, and suppressing inflammatory mechanisms in oral tissues [25, 30].

Radiodermatitis is frequent and multi-factorial radiotherapy side effect of radiotherapy, typically in the form of erythema and skin desquamation, and may result in changes or delays in cancer treatment regimens [26, 28]. Several RCTs have repeatedly demonstrated that the use of PBMT as a prophylaxis significantly minimizes the severity of radiodermatitis, enhances patient comfort, and results in overall quality of life improvement [26, 28-29, 31]. PBMT prophylactic action against radiodermatitis is through minimizing oxidative damage, modulation of proinflammatory cytokines, and enhancing skin regeneration and restoration of barrier function [31-33].

Chemotherapy-induced alopecia, with its devastating psychological effect, had already been treated with scalp

cooling and medication; the preventive effectiveness of such interventions, however, was modest [23]. Although limited evidence was available regarding PBMT in the treatment of chemotherapy-induced alopecia, its widely documented regenerative potential in dermatological treatment suggested potential therapeutic applications, and additional rigorous clinical trials were demanded [23].

In addition, PBMT has been promising as an effective adjuvant to cancer lymphedema treatment, which is identified by chronic swelling of the extremities, impaired limb function, and impaired patient mobility [24]. Traditional treatment of choice has been conservative management with compression and manual lymphatic drainage; however, PBMT's regenerative and antiinflammatory properties offer some therapeutic benefits that must be investigated in the context of oncologic rehabilitation strategies [24].

Current research has also found potential applications in cachexia cancer, a syndrome of extreme muscle loss that is common in advanced cancer patients [34]. Preclinical research has identified the PI3K/AKT/FoxO3a signaling pathway as a crucial pathway responsible for the ability of PBMT to modulate muscle injury and potentially improve

functional capacity and survival in cachexia cancer patients [34]. Concurrently, recent research has also explored the neuroprotective properties of PBMT and its potential as an intervention for chemotherapy-induced cognitive dysfunction, and thus a potential expansion of its therapeutic use [32].

In addition, long-term safety and survival outcomes of PBMT treatment in oncology have been extensively examined, allaving earlier fears of potential risks for tumor stimulation. Systematic reviews and longitudinal analyses, as well as all of them, confirm the safety profile of PBMT in oncologic usage, with no probable risk of tumor recurrence or formation with low-energy laser treatment [35]. Notably, fresh evidence indicates enhanced long-term survival in cancer patients who received PBMT for prevention and treatment of oral mucositis [35]. Additionally, PBMT also had extensive therapeutic applications, including home supportive treatment, offering convenient care interventions, particularly helpful in the event of healthcare disruptions such as the COVID-19 pandemic [36]. However, in spite of mounting evidence supportive of the clinical effectiveness of PBMT, many practical matters still remained to be examined, specifically relating to standardized dosing regimens, optimal wavelengths, irradiance, and timing protocols particular to each different type of cancer and treatment setting [36-37]. Further studies on patient compliance, standardization of PBMT treatment protocols, and thorough cost-effectiveness evaluation would be required to fully integrate PBMT into routine supportive oncology practice [36-38].

# **5. LIMITATIONS**

The current review is marred by many limitations. The fewer number of studies with heterogeneous PBMT protocols, varied follow-up times, and heterogeneous evaluation measures imposed generalizability and comparability constraints. The high heterogeneity observed for pain scores and mTNS measures also hindered the synthesis of combined effects. Moreover, poor reporting of some technical parameters, rates of compliance, and the absence of standardized documentation of adverse events also compromised the overall strength of the conclusions drawn.

# 6. RECOMMENDATIONS AND IMPLICATIONS FOR FUTURE RESEARCH

Future research on PBMT for chemotherapy-induced peripheral neuropathy must be planned to perform largescale, multicenter RCTs with optimal study design to achieve maximum reliability and external validity of results. Standardization of PBMT protocols like the availability of clear guidelines on optimal parameters like wavelength, power density, energy density, irradiation duration, number of sessions and frequencies, and the duration of PBMT course will be crucial to ensure maximum results reproducibility and comparability across trials. Incorporation of detailed description of patient compliance, adequate evaluation of adverse effects, and the costeffectiveness evaluation of treatments within the trials will be required to evaluate practical feasibility as well as the health-economic considerations. Extended duration followup for more than several weeks will be suitable to evaluate late effects of efficacy, safety, and the patient outcomes after PBMT. Patient-level predictors of response like the severity of initial neuropathy, type of tumor, or anticancer chemotherapy drugs may allow personalization of the treatment schedules. Future trials will also yield high-quality results amenable to development of evidence-based clinical guidelines and thus PBMT would become a component of supportive therapy algorithms for chemotherapy-induced peripheral neuropathy in cancer patients.

# 7. CONCLUSION

Based on the cumulative evidence from clinical trials analysed in this review, PBMT showed statistically significant advantage in reducing the severity of chemotherapy-induced peripheral neuropathy, neuropathy symptoms, and the severity of cancer pain. Across methodological diversity, PBMT consistently showed positive effects in diverse clinical outcomes, reflecting clinical usefulness as an adjunctive therapeutic intervention. However, owing to the large heterogeneity and limited methodological quality seen among studies included, the magnitude of benefits observed should be viewed with caution. Thus, PBMT was promising but needed to be further standardized and validated by appropriately designed, sufficiently powered studies to confirm these preliminary findings.

#### Acknowledgment

None.

#### Conflict of interest

The authors claim that they have no conflict of interest.

#### Funding

None.

**Ethical statement** 

#### References

1. Heiskanen V, Zadik Y, Elad S. Photobiomodulation Therapy for Cancer Treatment-Related Salivary Gland Dysfunction: A Systematic Review. Photobiomodul Photomed Laser Surg. 2020 Jun;38(6):340-347. doi: 10.1089/photob.2019.4767.

Robijns J, Nair RG, Lodewijckx J, Arany P, Barasch A, Bjordal JM, et al. Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022. Front Oncol. 2022 Aug 30;12:927685. doi: 10.3389/fonc.2022.927685.

3. Hamblin MR. Photobiomodulation Therapy for Treatment of Extravasation Injuries in Cancer Chemotherapy. Photobiomodul Photomed Laser Surg. 2023 Jan;41(1):1-2. doi: 10.1089/photob.2022.0126.

Kauark-Fontes E, Rodrigues-Oliveira L, Epstein JB, Faria KM, Araújo ALD, Gueiros LAM, et al. Cost-effectiveness of photobiomodulation therapy for the prevention and management of cancer treatment toxicities: a systematic review. Support Care Cancer. 2021 Jun;29(6):2875-2884. doi: 10.1007/s00520-020-05949-1.

5. Bensadoun RJ, Nair RG, Robijns J. Photobiomodulation for Side Effects of Cancer Therapy. Photobiomodul Photomed Laser Surg. 2020 Jun;38(6):323-325. doi: 10.1089/photob.2019.4759.

Rao D, Dsouza CN, Prabhu SS, Kumar P, Prabhu V. Photobiomodulation therapy for mitigating severity of radiodermatitis in cancer patients undergoing radiotherapy: a scoping review. Support Care Cancer. 2024 Oct 28;32(11):750. doi: 10.1007/s00520-024-08944-y.

7. Redman MG, Harris K, Phillips BS. Low-level laser therapy for oral mucositis in children with cancer. Arch Dis Child. 2022 Feb;107(2):128-133. doi: 10.1136/archdischild-2020-321216.

8. Zadik Y, Arany PR, Fregnani ER, Bossi P, Antunes HS, Bensadoun RJ, et al.; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO). Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019 Oct;27(10):3969-3983. doi: 10.1007/s00520-019-04890-2.

9. Yong J, Gröger S, VON Bremen J, Martins Marques M, Braun A, Chen X, et al. Photobiomodulation therapy assisted orthodontic tooth movement: potential implications, challenges, and new perspectives. J Zhejiang Univ Sci B. 2023 Sep 27;24(11):957-973. doi: 10.1631/jzus.B2200706.

10. Lin YT, Tung KM, Chiou JF, Chen YC, Hou WH. Effects of photobiomodulation therapy for acute radiation dermatitis in patients with cancer: A systematic review and meta-analysis of real-world evidence. Radiother Oncol. 2025 Jan;202:110589. doi: 10.1016/j.radonc.2024.110589.

11. Behroozian T, Bonomo P, Patel P, Kanee L, Finkelstein S, van den Hurk C, et al.; Multinational Association of Supportive Care in Cancer (MASCC) Oncodermatology Study Group Radiation Dermatitis Guidelines Working Group. Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recommendations. Lancet Oncol. 2023 Apr;24(4):e172-e185. doi: 10.1016/S1470-2045(23)00067-0.

12. de Pauli Paglioni M, Araújo ALD, Arboleda LPA, Palmier NR, Fonsêca JM, Gomes-Silva W, et al. Tumor safety and side effects of photobiomodulation therapy used for prevention and management of cancer treatment toxicities. A systematic review. Oral Oncol. 2019 Jun:93:21-28. doi: 10.1016/j.oraloncology.2019.04.004.

13. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, McKenzie JE. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021 Mar 29;372:n160. doi: 10.1136/bmj.n160. PMID: 33781993; PMCID: PMC8005925.

14. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T,

McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:14898. doi: 10.1136/bmj.14898. PMID: 31462531.

15. Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT, Boutron I, Carpenter JR, Chan AW, Churchill R, Deeks JJ, Hróbjartsson A, Kirkham J, Jüni P, Loke YK, Pigott TD, Ramsay CR, Regidor D, Rothstein HR, Sandhu L, Santaguida PL, Schünemann HJ, Shea B, Shrier I, Tugwell P, Turner L, Valentine JC, Waddington H, Waters E, Wells GA, Whiting PF, Higgins JP. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016 Oct 12;355:i4919. doi: 10.1136/bmj.i4919. PMID: 27733354; PMCID: PMC5062054.

16. Altaher AMA, Borhan WH, Abolkasem MA, Elkeblawy MM, Othman EM. Photo-biomodulation therapy for chemotherapy induced peripheral neuropathy in breast cancer patients. Afr J Bio Sci. 2024;6(12):6011-6022. doi:10.48047/AFJBS.6.12.2024.6011-6022.

17. Argenta PA, Ballman KV, Geller MA, Carson LF, Ghebre R, Mullany SA, Teoh DG, Winterhoff BJ, Rivard CL, Erickson BK. The effect of photobiomodulation on chemotherapy-induced peripheral neuropathy: A randomized, sham-controlled clinical trial. Gynecol Oncol. 2017 Jan;144(1):159-166. doi: 10.1016/j.ygyno.2016.11.013. Epub 2016 Nov 22. PMID: 27887804.

18. Joy, L., Jolien, R., Marithé, C. et al. The use of photobiomodulation therapy for the prevention of chemotherapy-induced peripheral neuropathy: a randomized, placebo-controlled pilot trial (NEUROLASER trial). Support Care Cancer 30, 5509–5517 (2022). https://doi.org/10.1007/s00520-022-06975-x

19. Lee, John & Look, Regan & Turner, Crystal & Gardiner, Stuart & Wagie, Terry & Douglas, Jeremy & Sorenson, Leslie & Evans, Laura & Kirchner, Sandra & Dashkoff, Cyd & Garrett, Karen & Johnson, Nathalie. (2012). Low-level laser therapy for chemotherapy-induced peripheral neuropathy.. Journal of Clinical Oncology. 30. 9019-9019. 10.1200/jco.2012.30.15\_suppl.9019.

20. Santamarina, Laura & Souza, Mariane & Sassaron, Larissa & Ezequiel, Talita & Carvalho, Regiane & Vilas Boas, Vanessa & Franco, Laura. (2025). Photobiomodulation on postural control and gait speed in chemotherapyinduced peripheral neuropathy. 10.21203/rs.3.rs-5814765/v1.

21. Teng C, Egger S, Blinman PL, Vardy JL. Evaluating laser photobiomodulation for chemotherapy-induced peripheral neuropathy: a randomised phase II trial. Support Care Cancer. 2022 Dec 17;31(1):52. doi: 10.1007/s00520-022-07463-y. PMID: 36526802; PMCID: PMC9758032.

22. Patel P, Robinson PD, Baggott C, Gibson P, Ljungman G, Massey N, et al. Clinical practice guideline for the prevention of oral and oropharyngeal mucositis in pediatric cancer and hematopoietic stem cell transplant patients: 2021 update. Eur J Cancer. 2021 Sep;154:92-101. doi: 10.1016/j.ejca.2021.05.013.

23. Wikramanayake TC, Haberland NI, Akhundlu A, Laboy Nieves A, Miteva M. Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming? Curr Oncol. 2023 Mar 25;30(4):3609-3626. doi: 10.3390/curroncol30040275.

24. Bergmann A, Baiocchi JMT, de Andrade MFC. Conservative treatment of lymphedema: the state of the art. J Vasc Bras. 2021 Oct 11;20:e20200091. doi: 10.1590/1677-5449.200091.

25. Pires Marques EC, Piccolo Lopes F, Nascimento IC, Morelli J, Pereira MV, Machado Meiken VM, et al. Photobiomodulation and photodynamic therapy for the treatment of oral mucositis in patients with cancer. Photodiagnosis Photodyn Ther. 2020 Mar;29:101621. doi: 10.1016/j.pdpdt.2019.101621.

26. Robijns J, Lodewijckx J, Mebis J. Photobiomodulation therapy for acute radiodermatitis. Curr Opin Oncol. 2019 Jul;31(4):291-298. doi: 10.1097/CCO.00000000000511.

27. Weusten BLAM, Bisschops R, Dinis-Ribeiro M, di Pietro M, Pech O, Spaander MCW, et al. Diagnosis and management of Barrett esophagus: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2023 Dec;55(12):1124-1146. doi: 10.1055/a-2176-2440.

28. Robijns J, Lodewijckx J, Claes S, Van Bever L, Pannekoeke L, Censabella S, et al. Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial). Radiother Oncol. 2021 May;158:268-275. doi: 10.1016/j.radonc.2021.03.002.

29. Robijns J, Lodewijckx J, Puts S, Vanmechelen S, Van Bever L, Claes S, et al. Photobiomodulation therapy for the prevention of acute radiation dermatitis in breast cancer patients undergoing hypofractioned whole-breast irradiation (LABRA trial). Lasers Surg Med. 2022 Mar;54(3):374-383. doi: 10.1002/lsm.23475.

30. Lee CT, Galloway TJ. Pathogenesis and Amelioration of Radiation-Induced Oral Mucositis. Curr Treat Options Oncol. 2022 Mar;23(3):311-324. doi: 10.1007/s11864-022-00959-z.

31. Gobbo M, Rico V, Marta GN, Caini S, Ryan Wolf J, van den Hurk C, et al. Photobiomodulation therapy for the prevention of acute radiation dermatitis: a systematic review and meta-analysis. Support Care Cancer. 2023 Mar 23;31(4):227. doi: 10.1007/s00520-023-07673-y.

32. Cardoso FDS, Gonzalez-Lima F, Gomes da Silva S. Photobiomodulation for the aging brain. Ageing Res Rev. 2021 Sep;70:101415. doi: 10.1016/j.arr.2021.101415.

33. Vieira Nascimento M, Costa FWG, de Oliveira Filho OV, Silva PGB, de Freitas Pontes KM. Management of Cancer Therapy-Induced Oral Mucositis Using Photobiomodulation Therapy: An Overview of Systematic Reviews. Photobiomodul Photomed Laser Surg. 2023 Oct;41(10):513-538. doi: 10.1089/photob.2023.0091.

34. Li Y, Chen Y, Liao Y, Huang T, Tang Q, He C, et al. Photobiomodulation therapy moderates cancer cachexia-associated muscle wasting through activating PI3K/AKT/FoxO3a pathway. Apoptosis. 2024 Jun;29(5-6):663-680. doi: 10.1007/s10495-024-01949-2.

35. Paiva DL, Oliveira VR, Bagnato VS, Simões A. Long-term survival of cancer patients after photobiomodulation therapy for prevention and treatment of oral mucositis. Photodiagnosis Photodyn Ther. 2024 Aug;48:104248. doi: 10.1016/j.pdpdt.2024.104248.

36. Lopez-Garzon M, López-Fernández MD, Ruíz-Martínez AM, Galván-Banqueri P, Lozano-Lozano M, Tovar-Martín I, et al. Efficacy of photobiomodulation therapy combined with mobile health education in patients with head and neck cancer suffering from chronic xerostomia after radiotherapy: protocol for a three-arm, randomised, placebo-controlled, double-blinded study. BMJ Open. 2024 Jan 24;14(1):e078068. doi: 10.1136/bmjopen-2023-078068.

37. Ramos Rocha S, da Costa Ferreira SA, Ramalho A, Conceição Gouveia Santos VL, Cristina Nogueira P. Photobiomodulation Therapy in the Prevention and Treatment of Radiodermatitis in Breast Cancer Patients: Systematic Review. J Lasers Med Sci. 2022 Oct 2;13:e42. doi: 10.34172/jlms.2022.42.

38. Fornaini C, Merigo E, Huffer KW, Arany P. At-Home Photobiomodulation Treatments for Supportive Cancer Care During the COVID-19 Pandemic. Photobiomodul Photomed Laser Surg. 2021 Feb;39(2):81-82. doi: 10.1089/photob.2020.4923.